PD-1/PD-L1在肝细胞癌中免疫调节作用的研究进展

Advances in Immunoregulation of PD-1/PD-L1 in Hepatocellular Carcinoma

肝细胞癌是世界上最常见的致死性肿瘤之一,程序性死亡蛋白-1(PD-1)和程序性死亡配体-1(PD-L1)这对免疫共抑制分子在肝癌细胞中广泛表达。目前以抗PD-1/PD-L1为靶点的免疫治疗在多种肿瘤中取得了良好而持久的疗效。然而PD-1/PD-L1在肝细胞癌微环境中的免疫调节机制尚待完善,是否对抗PD-1/PD-L1治疗敏感及如何联合其他治疗目前尚无定论。笔者主要对PD-1/PD-L1通路在肝细胞癌中的免疫调节及抗PD-1/PD-L1在肝细胞癌治疗方面的研究进展进行综述。

Hepatocellular carcinoma is one of the most common malignant tumors in the world, with procedural death protein - 1 （ PD - 1 ） and procedural death ligand - 1 （ PD - L1 ）. This pair of immunocompromised molecules is widely found in hepatocarcinoma cells expression. At present, anti - PD - 1/PD - L1 as the target of immunotherapy in a variety of tumors achieved good and lasting effect. However, the immunoregulatory mechanism of PD -1/PD -L1 in the mieroenviron- ment of hepatocellular carcinoma remains to be improved. Whether it is sensitive to PD - 1/PD - L1 treatment and how to combine other treatment is not conclusive. This review summarizes the advances in the immunoregulation of PD - 1/PD - L1 pathway in hepatocellular carcinoma and the progress of anti - PD - 1/PD - L1 in the treatment of hepatocellular carcinoma.